Chicago Event to Encourage Participation in Alzheimer’s Clinical Research

Event is on November 8, Chicago Alzheimer’s Awareness DayWASHINGTON, D.C. – On November 8th – Chicago Alzheimer’s Awareness Day – Great Lakes Clinical Trials and the Global Alzheimer’s Platform Foundation are hosting a major community event for people in the community who are interested in learning more about memory concerns and Alzheimer’s disease. Research volunteers, including care partners, are being […]

Read More…

Statement from Global Alzheimer’s Platform (GAP) Foundation on the National Strategy for Recruitment and Participation in Alzheimer’s Disease Clinical Research

WASHINGTON, D.C. – “I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its […]

Read More…

Global Alzheimer’s Platform Foundation Launches Citizen Scientist Awards®, A National Initiative Celebrating Clinical Trial Participants

WASHINGTON, D.C. – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical trial participants. The awards are designed to […]

Read More…

Global Alzheimer’s Platform (GAP) Foundation Launches Partnership with Lyft to Transport Clinical Trial Participants to and from Clinical Research Facilities Across North America

WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who are part of Eli Lilly and Company’s (Lilly) study TRAILBLAZER-ALZ, an Alzheimer’s disease […]

Read More…

Statement from Global Alzheimer’s Platform (GAP) Foundation in Response to Bill Gates’ Investment in Alzheimer’s Research

WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial […]

Read More…

Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA

More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked SitesKansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone.  It is projected that […]

Read More…

Global Alzheimer’s Platform Foundation Supports $400 Million Congressional Increase for Alzheimer’s Research Funding

Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National Institutes of Health (NIH) will receive a $2 billion boost in […]

Read More…

Global Alzheimer’s Platform Foundation Appoints Pascale Witz to Board of Directors

Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer’s Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will […]

Read More…

Global Alzheimer’s Platform Foundation Announces GAP-Net

First-of-its-Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP-Net, a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP-Net currently has 11 leading academic and private commercial research site partners. […]

Read More…

Global Alzheimer’s Platform Foundation Appoints Dr. Kate Zhong as Chief Strategy Officer

Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role WASHINGTON, D.C. – Global Alzheimer’s Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this role, Dr. Zhong […]

Read More…